1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 12 OCTOBER 2015

Cancer Drug News 12 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Second-To-Market Status Not Detrimental For Abemaciclib
Industry Trend Analysis - Kadcyla Compulsory Licence Request Will Increase Pricing Pressure For Roche
Industry Brief - BI/Philogen Partner To Develop Novel Therapies For AML
Industry Brief - Astex' Guadecitabine Gains FDA ODD For AML
Industry Trend Analysis - Keytruda's Long-Term Performance Outlook In NSCLC Favourable
Industry Brief - Verastem Reduces Workforce
Industry Brief - Keytruda Receives NICE Draft Recommendation For First-Line Treatment Of Advanced Melanoma
Industry Brief - FDA Grants Fast Track Designation To Avelumab For MCC
Industry Brief - Cotellic/Zelboraf Combination Improves OS In Advanced Melanoma
Industry Brief - Exelixis' Cobimetinib Achieves Positive OS Results In Phase III Melanoma Trial
Industry Brief - Lenvima Receives Approval In South Korea
Industry Trend Analysis - Genomics Becoming Integral Part Of Successful Drug Development
Industry Trend Analysis - Balancing Protection And Access Essential For EU Biosimilar Market To Succeed
Industry Brief - Oravig Launched In US

Table Of Contents

Cancer Drug News 12 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.